Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: A phase III, randomised, controlled trial (PALACE 3)

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 1065-1073

  Edwards, Christopher J ^a   Blanco, Francisco J ^b   Crowley, Jeffrey ^c   Birbara, Charles A ^d   Jaworski, Janusz ^e   Aelion, Jacob ^f   Stevens, Randall M ^g   Vessey, Adele ^g   Zhan, Xiaojiang ^g   Bird, Paul ^h  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b División de Reumatología INIBIC Hospital Universitario A Coruña   (Spain)

^c Bakersfield Dermatology   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e Reumatika Centrum Reumatologi   (Poland)

^f West Tennessee Neurosciences   (United States)

^g CELGENE CORPORATION   (United States)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE IV INHIBITOR; THALIDOMIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS ASSESSMENT; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; ANALOGS AND DERIVATIVES; ARTHRITIS, PSORIATIC; CLINICAL TRIAL; DOSE RESPONSE; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; SEVERITY OF ILLNESS INDEX; SKIN; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84956650037     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207963     Document Type: Article

References (25)

1. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14-17.
2. Sakkas LI, Alexiou I, Simopoulou T, et al. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum 2013;43:325-34.
3. Carneiro S, Bortoluzzo A, Goncalves C, et al. Effect of enthesitis on 1505 Brazilian patients with spondyloarthritis. J Rheumatol 2013;40:1719-25.
4. Strand V, Fiorentino D, Hu C, et al. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes 2013;11:82.
5. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012;51:1368-77.
6. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50.
7. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85.
8. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319-26.
9. Pereda CA, Nishishinya MB, Martinez Lopez JA, et al. Efficacy and safety of DMARDs in psoriatic arthritis: a systematic review. Clin Exp Rheumatol 2012;30:282-9.
10. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012;83:1583-90.
11. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020-6.
12. Adebajo AO, Gladman DD, Kavanaugh A, et al. Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase III, randomized, controlled trial and open-label extension (PALACE 1) [abstract 217]. Rheumatology (Oxford) 2015;54 (Suppl 1):i133.
13. El Miedany Y. Recent developments in management of psoriatic arthritis. Curr Rheumatol Rev 2005;1:9-19.
14. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
15. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003;30: 167-78.
16. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127-32.
17. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64:3156-67.
18. Mease PJ, Ganguly R, Wanke L, et al. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines [abstract SAT0015]. Ann Rheum Dis 2004;63(Suppl 1):391.
19. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]). J Am Acad Dermatol 2015;73:37-49.
20. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol 2015;173:1387-99.
21. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137-74.
22. Wong PC, Leung YY, Li EK, et al. Measuring disease activity in psoriatic arthritis. Int J Rheumatol 2012;2012:839425.
23. Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013;72:1777-85.
24. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008;35:869-76.
25. Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014;370:2295-306.